Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

492
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
492
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

521
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
521
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

235
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
235
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

442
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
442
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

493
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
493

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment Outcomes in Older Adults With Hidradenitis Suppurativa: A Multimodal Approach.

International journal of dermatology·2026
Same author

Sociodemographic Disparities in Pediatric Dermatological Conditions: Insights From the 2019 Global Burden of Disease Project.

Pediatric discovery·2026
Same author

Association of Comorbid Trauma and Stressor-Related Disorders in Pemphigus and Pemphigoid: A Case-Control Study.

The Journal of dermatology·2026
Same author

Breaking the cycle: successful long-term remission of chronic erythema multiforme with rituximab therapy.

Skin health and disease·2026
Same author

Psychocutaneous Disorders in Pediatric and Adolescent Populations: A Narrative Review.

American journal of clinical dermatology·2026
Same author

Cross-Cultural Beliefs and Stigmatization in Vitiligo: A Systematic Review.

Journal of cosmetic dermatology·2026

Related Experiment Video

Updated: Jan 16, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

3.8K

Targeted Biologic Therapies for Hidradenitis Suppurativa.

Isabella J Tan1, Helen N Nguyen2, Sydney M Wolfe1

  • 1Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, Piscataway, NJ 08901, USA.

International Journal of Molecular Sciences
|September 27, 2025
PubMed
Summary

Biologic therapies targeting interleukins and TNF-α show promise for hidradenitis suppurativa (HS). These agents offer improved quality of life and reduced inflammation, though further research is needed.

Keywords:
chronic inflammatory disorders of the apocrine glandhidradenitis suppurativatargeted therapy

More Related Videos

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

11.0K
Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.7K

Related Experiment Videos

Last Updated: Jan 16, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

3.8K
High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

11.0K
Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.7K

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Chronic inflammatory disorders of the apocrine gland (CIDAP), including hidradenitis suppurativa (HS), present as painful, recurrent lesions.
  • Standard treatments like retinoids and antibiotics frequently fail, leading to recurrence and biofilm formation.
  • Biologic therapies are increasingly necessary for effective HS management.

Purpose of the Study:

  • To review U.S.-based randomized controlled trials and cohort studies from 2014-2024 on biologic therapies for adult HS.
  • To assess the efficacy and safety of agents targeting interleukins (IL-17A, IL-17F, IL-23, IL-1α, IL-36) and TNF-α.
  • To evaluate outcomes such as HiSCR, Sartorius scores, DLQI, and patient-reported measures.

Main Methods:

  • Systematic review of 13 U.S.-based studies (RCTs and cohort studies) published between 2014 and 2024.
  • Included adult patients with hidradenitis suppurativa (HS).
  • Assessed efficacy of biologic agents targeting IL-17, IL-23, IL-1, and TNF-α.

Main Results:

  • IL-17 inhibitors (secukinumab, bimekizumab) and IL-1 inhibitors (bermekimab, anakinra) showed significant reductions in inflammation and improved quality of life.
  • TNF-α inhibitors (adalimumab, infliximab) consistently improved HiSCR and HSS scores.
  • Guselkumab (IL-23) demonstrated modest pain relief but limited HiSCR efficacy. Safety profiles were generally acceptable.

Conclusions:

  • Biologic agents targeting IL-17, IL-1, and TNF-α hold significant therapeutic potential for managing hidradenitis suppurativa (HS).
  • Improvements in inflammatory burden and quality of life were observed.
  • Future management should emphasize biomarker-guided selection and interdisciplinary care for optimal long-term outcomes.